featured
Pembrolizumab vs Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study
Lancet 2018 Nov 30;[EPub Ahead of Print], EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, A Soria, JP Machiels, N Mach, R Mehra, B Burtness, P Zhang, J Cheng, RF Swaby, KJ HarringtonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.